Angela Bray Lindsay, Noah J Levy, Margaret L McAndrew
Journal: Emergency medicine clinics of North America 2025;43(3):453-461
PMID: 40610062
Tumor lysis syndrome (TLS) is an oncologic emergency that occurs due to the massive lysis of tumor cells resulting in hyperkalemia, hyperuricemia, hyperphosphatemia, and hypocalcemia. Patients are at significant risk for acute kidney injury, arrhythmia, seizures, and sudden death as sequelae of this condition. Management is dependent on severity but often includes acute stabilization, aggressive hydration, correction of electrolyte abnormalities, and uric acid-lowering medications, such as rasburicase and allopurinol. TLS carries high morbidity and mortality risk making prevention through intravenous hydration and prophylactic medications the best management strategy.
Copyright © 2025 Elsevier Inc. All rights reserved.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.